Stay updated with breaking news from Formycon Ag. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investegate announcements from Formycon AG, Formycon announces EU-Approval of FYB201/Ranivisio®1 a biosimilar to Lucentis®2
Investegate announcements from Formycon AG, Formycon announces FDA approval of FYB201/CIMERLITM1 (ranibizumab-eqrn) as a Biosimilar interchangeable with Lucentis®2
Investegate announcements from Formycon AG, FYB201, Formycon's biosimilar for Lucentis® (ranibizumab), receives CHMP recommendation from EMA
Investegate announcements from Formycon AG, Formycon is acquiring the biosimilar assets FYB201 and FYB202 and strengthening its position in the global growth market of biosimilars through long-term partnership with ATHOS KG
Investegate announcements from Formycon AG, Formycon Concludes Collaboration and License Agreement with SCG Cell Therapy for its COVID-19 Drug FYB207 for the Asia Pacific Region